United Therapeutics (UTHR) Net Cash Flow (QoQ) (2009 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) Net Cash Flow (QoQ) (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.87 Bn | 624.11 Bn | 17.26 Bn |
| 2 | AbbVie | 440.91 Bn | 434.35 Bn | 12.70 Bn |
| 3 | Merck | 366.10 Bn | 358.96 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.00 Bn | 259.31 Bn | 11.24 Bn |
| 5 | Pfizer | 159.23 Bn | 147.53 Bn | 10.94 Bn |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.24 Bn | 44.24 Bn | - |
| 8 | Incyte | 25.34 Bn | 20.80 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.48 Bn | 18.82 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 288.72% |
| Mar 31, 2026 | -227.83% |
| Dec 31, 2025 | 185.77% |
| Sep 30, 2025 | 17.54% |
| Jun 30, 2025 | -251.36% |
| Mar 31, 2025 | 41.45% |
| Dec 31, 2024 | -27.70% |
| Sep 30, 2024 | 90.21% |
| Jun 30, 2024 | 137.90% |
| Mar 31, 2024 | -56.20% |
| Dec 31, 2023 | 147.52% |
| Sep 30, 2023 | 142.00% |
| Jun 30, 2023 | -147.55% |
| Mar 31, 2023 | 3,712.50% |
| Dec 31, 2022 | -103.26% |
| Sep 30, 2022 | 1,048.07% |
| Jun 30, 2022 | 77.79% |
| Mar 31, 2022 | -494.89% |
| Dec 31, 2021 | 59.35% |
| Sep 30, 2021 | -130.66% |